Wednesday Morning in Dresden
Welcome to Day Three of LC•GC Europe’s HPLC 2009 Show Daily.The Wednesday morning parallel sessions kick off with a second round of seminars on Biopharmaeutical and Biomedical Analysis and Electroseparations chaired by Steve Cohen and Gerard Rozing and a session on Multidimensional Separations, chaired by Martin Gilar.
The first seminar in Multidimensional Separations section by Tyge Greibrokk assesses the advantages and limitations of multidimensional LC and is followed by Paola Dugo with a talk on different approaches to obtain high peak capacities in HPLC separations. Xiangmin Zhang describes his work on integrating multidimensional chromatography mass spectrometric methods for intact protein analysis and Sebastian Eeltnik reveals his findings on the design of monolithic columns for maximizing the LC performance in two-dimensional chromatography for the separation of complex proteomics samples in the concluding lecture.
The Biopharmaeutical and Biomedical Analysis section starts with a lecture by Barry Karger on the comprehensive characterization of protein targets and biopharamaceuticals using advanced LC–MS and CE–MS methods. Hanno Stutz then describes comprehensive characterization of diagnostic recombinant allergen products with complementary CE strategies and Frank Sinner will describe the role of ring-opening metathesis polymerization-derived capillary monoliths in modern biomedical research. Egidijus Machtejevas concludes with an overview of 2D LC for the analysis of complex peptide samples.
Capillary electrochromatography and molecular dynamics simulations in human nanoscale interaction studies is discussed by Marja-Lisa Riekkola in the first Electroseparations session, followed by a talk by H. Watzig on precision in capillary isoelelectric focusing for long-term protein analysis. Markus Martin will discuss using CE–ESI-MS–MS as a rapid screening tool for determining protein–ligand interactions and binding constants and David Goodall describes selective focusing of charged analytes in electrically-assisted LC on monolithic media.
The next round of parallel sessions on Wednesday on Monoliths, Proteomics and Pharmaceutical Analysis are chaired by Nobuo Tanaka, Peter Oefner and Pat Sandra respectively.
Frantisek Svec kicks off the session on Monoliths with a lecture on the art of pore surface functionalization to prepare monoliths tailored for specific applications, followed by Michael Buchmeiser on electron-beam curing and ROMP-derived monolithic devices. The purification of biomacromolecules using methacrylate monoliths is described by Ales Podgornik and Andreas Greiderer assesses the influence of polymerization time on porous properties of organic monolithic stationary phases.
Part two of the Proteomics sessions begins with a talk by Fred Regnier engagingly titled Humans are More Stressed Than We Realize: Oxidation of Proteins and is followed by Alan Van Dorsselaer on genome annotation and TMPP derivitization. Oliver Kohlbacher discusses how to make the most of your data in high throughput proteomics data. This section ends with a lecture on the development of a high resolution MudPit method for the identification of neuroproteins in mice by Karl Mechtler
The Pharmaceutical Analysis sessions begin with a talk on the separation of pharmaceutical compounds at high temperatures using HPLC by Roger Smith, followed by Xiaoli Wang on the critical comparison of sub-2 µm particles and superficially porous particles under optimized ultra-high pressure conditions in pharmaceutical analysis. Caterina Temporini describes the use of frontal affinity chromatography with MS to identify potential drug candidates and Pawl Wiczling discusses the role of gradient reversed-phase HPLC to lipophilicity and the pKa determination of drugs.
Poster sessions and vendor seminars take place during the lunchbreak.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.